Differential effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes

被引：0
|
作者：
Stocker, DJ [1 ]
Taylor, AJ [1 ]
Jezior, MR [1 ]
Langley, RW [1 ]
Vigersky, RA [1 ]
机构：
[1] Walter Reed Army Med Ctr, Washington, DC 20307 USA
来源：
CIRCULATION | 2005年 / 112卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3825
引用
收藏
页码：U906 / U906
页数：1
相关论文
共 50 条
  • [21] Rosiglitazone in combination with metformin effectively reduces hyperglycemia in patients with type 2 diabetes.
    Fonseca, V
    Biswas, N
    Salzman, A
    DIABETOLOGIA, 1999, 42 : A230 - A230
  • [22] Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes
    Chu, NV
    Caulfield, M
    Kong, APS
    Mudaliar, SR
    Kim, DD
    Reitz, R
    Armstrong, D
    Henry, RR
    Baxi, S
    Reaven, PD
    Deutsch, R
    DIABETES CARE, 2002, 25 (03) : 542 - 549
  • [23] Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes
    Christian Herder
    Norbert Hermanns
    Seminars in Immunopathology, 2019, 41 : 477 - 489
  • [24] Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes
    Herder, Christian
    Hermanns, Norbert
    SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (04) : 477 - 489
  • [25] Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in Type 2 diabetes mellitus
    Kelley, DE
    McKolanis, TM
    Kelley, CA
    DIABETOLOGIA, 2002, 45 : A188 - A188
  • [26] Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus
    Kelley, DE
    Mckolanis, TM
    Kelley, CA
    DIABETES, 2002, 51 : A35 - A35
  • [27] The QT Interval Could be a Marker of Subclinical Atherosclerosis in Patients with Type 2 Diabetes
    Hashimoto, Yoshitaka
    Tanaka, Muhei
    Senmaru, Takafumi
    Okada, Hiroshi
    Asano, Mai
    Yamazaki, Masahiro
    Oda, Yohei
    Hasegawa, Goji
    Nakamura, Naoto
    Fukui, Michiaki
    JOURNAL OF DIABETES & METABOLISM, 2014, 5
  • [28] The QT Interval Could be a Marker of Subclinical Atherosclerosis in Patients with Type 2 Diabetes
    Hashimoto, Yoshitaka
    Tanaka, Muhei
    Senmaru, Takafumi
    Okada, Hiroshi
    Asano, Mai
    Yamazaki, Masahiro
    Oda, Yohei
    Hasegawa, Goji
    Nakamura, Naoto
    Fukui, Michiaki
    JOURNAL OF DIABETES & METABOLISM, 2014, 5 (01)
  • [29] Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome
    Derosa, G
    Gaddi, AV
    Piccinni, MN
    Ciccarelli, L
    Salvadeo, S
    Peros, E
    Ghelfi, M
    Ferrari, I
    Cicero, AFG
    PHARMACOTHERAPY, 2005, 25 (05): : 637 - 645
  • [30] Relationships Between Measures of Adiposity with Subclinical Atherosclerosis in Patients with Type 2 Diabetes
    Yuan, Mingxia
    Hsu, Fang-Chi
    Bowden, Donald W.
    Xu, Jianzhao
    Smith, S. Carrie
    Wagenknecht, Lynne E.
    Comeau, Mary E.
    Divers, Jasmin
    Register, Thomas C.
    Carr, J. Jeffrey
    Langefeld, Carl D.
    Freedman, Barry I.
    OBESITY, 2016, 24 (08) : 1810 - 1818
12345